Overview

Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto (Sacubitril and Valsartan) Tablets (97 mg/103 mg)

Status:
COMPLETED

Trial end date:
2025-03-17

Target enrollment:

Participant gender:

Summary

An open label, balanced, randomized, single dose, two treatment, two sequence, four period, full-replicate, oral bioequivalence Study of Sacubitril and Valsartan 97 mg/103 mg Tablets of HUMANS SALIK ANONM RKET .O.S.B., Karaaa Mahallesi Fatih, Bulvar No:32, Kapakl/TEKRDA and Entresto (Sacubitril and Valsartan) 97 mg/103 mg Tablets of Novartis Europharm Limited, Irija in healthy, adult, human subjects under fasting condition.

Phase:

PHASE1

Details

Lead Sponsor:

Humanis Saglk Anonim Sirketi

Treatments:

sacubitril